Biophytis SA (FR:ALBPS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biophytis SA, a biotech firm, has signed an exclusive deal potentially worth €108M with Blanver for the rights to market their lead drug candidate BIO101 in Latin America. This partnership could also yield Biophytis double-digit royalties on BIO101’s future sales in the region. The collaboration includes joint clinical development and manufacturing for the treatment of diseases such as obesity and Duchenne Muscular Dystrophy.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.